Herrera SA, García HM

Language: Spanish
References: 13
Page:
PDF size: 85.27 Kb.

ABSTRACT

Cancer is actually one of the most important health problems in the occidental countries. In Cuba, cancer is the second cause of death in all ages, under heart diseases. In Matanzas, in the last years cancer had showed and ascending growth on incidence and prevalence, over country media. That is wy, we make this study with the objective to evaluate the impact of inmunotherapy as a therapeutic alternative which increase the survival function in patients with advanced cancer.

REFERENCES

1. Arnedillo Muñoz A, Merino Sánchez M. Epidemiología del Cáncer de pulmón en el ámbito de Neumosur [Internet]. Rev Española de patología torácica. 2017[ citado 23/06/2020] (Supl marzo). Disponible en: Disponible en: https://www.neumosur.net/publicaciones_consensos_neumosur_contenidos.php?id=21

2. Gospodarowicz MK, Cazap E, Jadad AR. Cancer in the world: a call for international collaboration. Salud Pública Méx. 2009; 51(Suppl 2): p. s305-8. Citado en PubMed;PMID:19967286.

3. Saurez Martínez G, Bencomo Yanes A. Nimotuzumab, effective immunotherapy for the treatment of malignant epithelial tumor. Biotecnol Apl [Internet]. 2014 [citado 28/01/2016];31(2). Disponible en: Disponible en: http://scielo.sld.cu/scielo.php?script=sci_abstract&pid=S1027-28522014000200007

4. Reck M. What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer? Ann Oncol. 2012; 23 Suppl 8: p. 28-34. Citado en PubMed;PMID: 22918925.

5. Hall RD, Gray JE, Chiappori AA. Beyond the Standard of Care: A Review of Novel Immunotherapy Trials for the Treatment of Lung Cancer. Cancer Cont [Internet]. 2013[citado 23/09/2017]; 20: p. 22- 31. Disponible en: Disponible en: https://europepmc.org/article/med/23302904

6. Callahan MK, Wolchok JD, Allison JP. Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin Oncol. 2010; 37:437-84. Citado en PubMed;PMID:21074063.

7. Ramalingam S, Crawford J, Chang A, et al. Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial). Annals Oncol [Internet]. 2013[citado 23/09/2018]; 24: p. 2875-2880. Disponible en: Disponible en: https://www.annalsofoncology.org/article/S0923-7534(19)37370-3/abstract

8. Yu D, Cheng X, Liu Z, Xu S. Comparative beneficiary effects of immunotherapy against chemotherapy in patients with advanced NSCLC: Meta-analysis and systematic review. Oncol Lett. 2017 ;14(2):1568-80. Citado en PubMed;PMID:2878381.

9. Casciato DA. Manual de Oncología Clínica[Internet]. 8va ed. Filadelfia: Wolters Klubber[citado 23/09/2018]; 2017. Disponible en: Disponible en: http://ovides.ovid.com/Pages/book.aspx?isbn=9788496921344&division=fob

10. MINSAP. Anuario Estadístico de Salud [Internet]. República de Cuba: MINSAP[citado 23/09/2018]; 2016. Disponible en: Disponible en: https://files.sld.cu/bvscuba/files/2019/04/Anuario-Electr%c3%b3nico-Espa%c3%b1ol-2018-ed-2019-compressed.pdf

11. Escarlata López MD. El paciente oncológico. Atención compartida[Internet]. Granada: Hospital La Inmaculada[citado 23/09/2018]; 2016. Disponible en: Disponible en: http://congresos-semg.es/granada2016/images/stories/recursos/doc_complementaria/El-Medico-pregunta-El-experto-responde-Dra-Escarlata-Lopez.pdf

12. Bender E. Cancer immunotherapy. Nature 2017 ; 552(7685):S61. Citado en PubMed;PMID:29293244.

13. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell esponse. Nat Rev Immunology. 2012; 12: 269-81. Citado en PubMed;PMID:22437939.